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Background. We have reviewed our management, of both ruptured and non-ruptured, abdominal and thoraco-abdominal
mycotic aneurysms in order to determine the safety and efficacy of in situ and extra-anatomical prosthetic repairs.
Methods. Data regarding presenting symptoms, investigations, operative techniques and outcome, were collected on
patients treated at a singe centre over 11 years.
Results. There were 11 men and four women, with a median age of 70 years (range, 24–79). All but one patient were
symptomatic and six had a contained leak on admission. In six patients no organisms were identified in either blood or tissue
cultures. Pre-operative CT identified; four infra-renal, four juxta-renal, three (Crawford thoraco-abdominal) type IV, three
type III and one type II, aortic aneurysms. Thirteen were repaired with in situ prostheses and two required axillo-femoral
prosthetic grafts. There were four early deaths. All surviving patients have been followed-up for a median duration of 38
months (range 1/2–112 months). There were two late deaths at 3 months (juxta-renal) and at 2 years (type III), the latter
relating to graft infection.
Conclusions. In the absence of uncontrolled sepsis, repair of mycotic aortic aneurysms using prosthetic grafts can achieve
durable results.
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Introduction
Mycotic aortic aneurysms present a surgical challenge
and are associated with a high morbidity and
mortality. They constitute an uncommon hetero-
geneous pathologic entity with a reported incidence
of 1–3% of all abdominal aortic aneurysms.1 In 1885
William Osler described a 30-year-old man who died
after a period of diarrhoea, chills, headache, cough and
fever. Post-mortem examination revealed an aortic
valve consumed with vegetations, and in the aortic
arch four aneurysms had developed as a consequence
of endocarditis. These represented a case of mycotic
endarteritis and the largest of these aneurysms had
perforated and ruptured into the pericardium. Thus
the term mycotic aneurysm was introduced which is
somewhat misleading as the majority of aortic infec-
tions nowadays are bacterial, thus some authors prefer
to use the term ‘infected aneurysm’.2,3
The predominant micro-organisms associated with
mycotic aortic aneurysms are Staphylococcus species
(30%), Streptococcus species (10%) and Salmonella
species (10%).4 Fungal infections are rare and usually
associated with immunosuppressive states, diabetes
mellitus and the use of contaminated needles by drug
abusers.5 In South Africa HIV is now the commonest
cause.6
In this paper, we have reviewed our management of
both ruptured and non-ruptured, abdominal and
thoraco-abdominal mycotic aneurysms in order to
determine the safety and efficacy of in situ and extra-
anatomical prosthetic repairs.
Methods
During a 11-year period from 1991 to 2001, 15 patients
with primarily infected aortic aneurysms distal to the
left subclavian artery were treated at the Regional
Vascular Unit, St Mary’s Hospital, London, UK.
Patients were identified through the prospectively
collected Vascular Unit Surgery Registry. Detailed data
regarding these patients were gathered in a thorough
review of each medical record. Excluded from the
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study were patients treated for prosthetic graft
infections, infections of the ascending aorta and aortic
arch, arterial infections secondary to trauma, and
patients with positive routine cultures of aneurysm
contents. Patients were assessed for age, gender, site of
aortic infection, clinical presentation, leukocytosis
(white cell count .10,000), fever (temperature
.38 8C at presentation), results of blood and intra-
operative cultures, complicating conditions related to
the aortic infection such as free rupture, aortocaval
fistula, aortoenteric fistula, and other sites of arterial
infection, operative and long-term survival, and free-
dom from late prosthetic graft or arterial infection.
Results
Eleven men and four women, with a median age of 70
years (range, 24–79) with primarily infected aortic
aneurysms were treated over the study period
(Table 1). All but one patient were symptomatic. The
one asymptomatic patient had an associated psoas
abscess drained the month previously. Nine had back
pain, five were pyrexial, six had a raised white cell
count, and six were anaemic. Pre-operative CT
identified four infra-renal, four juxta-renal, three
(Crawford thoraco-abdominal) type IV, three type III
and one type II, aortic aneurysms. Of these, six had a
contained leak on admission: three infra-renal, one
type IV, one type III and one type II aneurysms.
Blood or tissue cultures isolated Salmonella ðn ¼ 3Þ;
Staphylococci ðn ¼ 3Þ; Streptococci ðn ¼ 1Þ; coliforms
ðn ¼ 1Þ; Treponema pallidum ðn ¼ 1Þ; while in six
patients no organisms were identified (Table 1). All
six patients that presented with sterile blood and
tissue cultures were already on empirical antibiotic
treatment commenced by the referring centre. How-
ever, CT scanning was highly suspicious of aortic
infection as there was evidence of gas in the aortic wall
of a saccular aneurysm. In addition, intra-operative
findings for all six patients included purulent peri-
aortic collections convincing of aortic infection.
Infra-renal aortic infections were treated with
extensive tissue debridement and in situ prosthetic
graft replacement, unless contamination was thought
to be too extensive in which case an extra-anatomical
bypass was performed and the aortic stump closed off
after excision of the aneurysm. Oral antibiotics were
continued for up to 3 months postoperatively. Supra-
renal infections were approached through a thoraco-
abdominal incision. All patients underwent aortic and
periaortic tissue debridement and in situ prosthetic
graft replacement. Operative survivors were placed on
antibiotics for a period of 3 months.
Thirteen were repaired with in situ prostheses
following extensive local debridement. Two patients
required axillo-femoral prosthetic grafts one of which
was found to have an aorto-duodenal fistula at the
time of surgery. There were four early deaths, two
(type IV) relating to blood loss, one secondary to
myocardial event (type IV) and one secondary to
multi-organ failure (juxta-renal). All surviving
patients have been followed-up for a median duration
of 38 months (range 1/2–112 months). There were two
late deaths at 3 months (juxta-renal) and at 2 years
(type III), the latter relating to graft infection.
Discussion
In comparison to non-infected aortic aneurysms,
mycotic aneurysms are more likely to be symptomatic.
The majority present with pyrexia, a raised white cell
count, and up to 50% may have positive blood
Table 1. Patients with mycotic aneurysms and outcomes
Sex Age Symptomatic Leaking Culture Type Repair Death
1 M 79 Yes Yes 2ve IV In situ Early
2 F 75 No No 2ve JR Ax-fem Early
3 M 59 Yes No 2ve JR Ax-fem Late
4 M 79 Yes Yes Salmonella IR In situ No
5 M 58 Yes No 2ve JR In situ No
6 M 71 Yes No Salmonella JR In situ No
7 F 70 Yes Yes Coliforms III In situ No
8 M 65 Yes No 2ve III In situ Late
9 F 71 Yes No Salmonella IR In situ No
10 M 74 Yes Yes 2ve IR In situ No
11 M 59 Yes No T. pallidum III In situ No
12 F 24 Yes Yes Staph. II In situ No
13 M 63 Yes No Strep. IV In situ Early
14 M 78 Yes No Staph. IV In situ Early
15 M 60 Yes Yes Staph. IR In situ No
JR, Juxta-renal; IR, Infra-renal; Ax-fem, Axillo-femoral.
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cultures.3 Radiographic studies are of great value in
the diagnosis and planning of the operation. CT
imaging may reveal rapid expansion of a known
aneurysm or a newly developed aneurysm, gas in the
aortic wall, extravasation of contrast in the periaortic
tissues, a saccular aneurysm, or a soft tissue mass
surrounding the aorta often accompanied by calcified
atherosclerotic plaque7,8 (Fig. 1). MRI can be of similar
use to CT scan, although not used in our series.9
Aortography may reveal a saccular, eccentric, or
multilobulated appearance in an otherwise normal
aorta (Fig. 2).
Controversy exists about the best operative option
for infra-renal mycotic aortic aneurysms. Some
authors advocate proximal and distal arterial ligation,
aneurysm resection with thorough debridement of
surrounding infected tissues and extra-anatomic
bypass in the form of either an axillo-bifemoral or
two axillo-unifemoral grafts.10 – 14 The risks of this
approach include aortic stump rupture and a higher
risk of thrombosis of the extra-anatomical bypass graft
compared to an inline graft.15 – 17 Alternatively, others
have published on the use of inline or in situ graft
placement following thorough debridement of the
infected field.18 – 21 This can be achieved either by
using standard prosthetic Dacron grafts, arterial
homografts, or superficial femoral venous grafts.
Review of the literature on the use of Dacron grafts
for in situ prosthetic reconstructions shows rather poor
results, with an approximately 25% early mortality
and a similar incidence of aortic septic complications
and vascular re-interventions.1,22 Moreover, it has
been suggested that some 20% of survivors following
in situ reconstruction need a subsequent extra-
anatomic bypass graft owing to infection of the initial
graft.23 In order to reduce the risk of infection of in situ
grafts it is recommended that they are soaked in
rifampicin.17,24,25 Also, the intra-operative application
of gentamicin releasing carriers has been reported.26
Neither of these antibiotic treatments are proven.
Some authors have taken a selective approach
whereby in situ reconstruction was performed in
cases of low-grade infection as indicated by a well-
circumscribed inflammatory process in the absence
of pus. This is typical of salmonella infection and
under these circumstances we place an in situ Dacron
graft. Conversely, if severe purulent infection is seen,
we usually perform an extra-anatomical bypass if
possible.3 Fichelle et al. in their personal series of 25
infected infra-renal aortic aneurysm operations in
which an in situ reconstruction of the aorta was used
in 21 patients, only three deaths were related to the
initial surgery (14%). In addition, none of the surviv-
ing patients showed any sign of a late septic
recurrence. In the group of four patients who under-
went extra-anatomic bypass, two died in the post-
operative period and one underwent re-operation 2
years after the initial surgery.22 Similarly, in our series
of four infra-renal and four juxta-renal mycotic aortic
aneurysms, six were repaired with in situ prostheses
following extensive local debridement and two
required axillo-femoral prosthetic grafts because of
severe purulent infection. There was one early death
secondary to multi-organ failure in one of the patients
that had an axillo-femoral graft and one late death
from unrelated causes.
In recent years there has been a renewed interest in
the use of cryopreserved arterial homografts although
the risk of aneurismal dilatation remains,21,27 Both
Szilagyi et al. and Kieffer et al. published favourable
results with arterial homografts.28,29 A number of
authors have documented the use the superficial
femoral vein (SFV) as an arterial substitute in the
repair of both non-leaking and leaking mycotic aortic
aneurysms as well as for infected aorto-iliac grafts. The
advantage of this conduit over the rest is that it is
resistant to infection and is not prone to aneurismal
dilatation.30 – 32 However, the operative time is invari-
ably longer and there are morbidity issues relating to
the leg incisions.
Intensive antibiotic therapy is crucial for successful
treatment of infected aortic aneurysms and should be
started in the pre-operative period.24 The optimum
duration of antibiotic therapy is still uncertain with
recommendations ranging from 6 weeks to lifelong
treatment.24,33,34 Most authors including ourselves
Fig. 1. Angiogram showing a localised saccular aneurysm
(blow-out) of the aortic wall, a typical appearance of a
mycotic aneurysm.
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would recommend a 3–6 month course of post-
operative antibiotic therapy at which stage it can be
discontinued provided there is no clinical, haemato-
logical or radiological evidence of ongoing sepsis.3
Infection involving the suprarenal and thoraco-
abdominal aorta poses distinct challenges due to the
necessity of visceral revascularisation. In each case
the visceral grafts must come in proximity to the
infected supra-renal aorta. Since 1962 fewer than 50
patients have been reported in the English language
literature. In addition, a variety of reconstructive
techniques have been used making comparative
conclusions difficult.35 Some have reported resection
of a supra-celiac aneurysm with closure of the aortic
stump and reconstruction with an axillo-bifemoral
graft that perfused the distal aorta and visceral
arteries retrogradely.36 The concern with this extra-
anatomical bypass is that flow will be inadequate
for viscera and legs, as well as an increased risk of
thrombosis.37 The majority of patients with infected
thoraco-abdominal aortic aneurysms have been
treated by resection of the visceral aorta, graft inter-
position, and reperfusion of the visceral vessels by
either ‘side-arm’ grafts or direct reattachment to the
aortic graft.33,35 In our series of seven mycotic
thoraco-abdominal aneurysms all were repaired
with inline Dacron grafts. Two of the type IV
mycotic thoraco-abdominal aneurysms died within
30 days of surgery. One of the type III repairs re-
presented with graft infection after 2 years and died
as a result. Although the numbers are small the 20%
re-intervention rate amongst survivors is similar to
that generally reported in the literature.1,22,23
In conclusion, our data of abdominal and thoraco-
abdominal mycotic aneurysms indicate that although
operative mortality is high, in the absence of severe
purulent infection repair using prosthetic grafts can
achieve durable results.
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